Here's Why Renewable Energy Group Is Plunging Today
The company might be a biomass-based diesel leader, but it's still dependent on the price of crude oil.
Here's Why Iovance Biotherapeutics Jumped 51.3% in February
Rumors of a buyout swirled around the biopharma.
Here's Why Axsome Therapeutics Fell 10.2% in February
The development-stage pharmaceutical company gave up a little ground, but important updates are right around the corner.
5 Numbers Repligen Investors Need to Know
Drilling down in the numbers shows how the bioprocess leader became one of the best growth stocks on the market -- and how it remains well-positioned for long-term growth.
Essential Utilities Takes Environmental Lead in Water, Nears Natural Gas Integration
Shares of the electric and gas utility were pounded in the broader market correction, but the long-term potential remains intact.
Here's My Top Stock to Buy in March
This cellular therapy developer is valued at $2.3 billion. That could be a bargain if clinical programs impress in 2020.
What to Watch When Renewable Energy Group Reports 2019 Results
There's really only one thing that matters to its investors with a long-term mindset: renewable diesel.
Strong Growth From NeoGenomics No Match for Economic Anxieties
Growth stocks have been getting punished in the current market downturn, but investors with a long-term mindset will find plenty to like in the latest earnings report.
Here's Why Omeros Corporation Stock Rose as Much as 46.5% Today
The company reported full-year 2019 operating results and a separate update from the pipeline.
Here's Why Momenta Pharmaceuticals Stock Rose 10.8% on Monday
Investors ran back into the stock after one of the worst weeks in market history. Will it prove sustainable?
U.S. Coal-Fired Power Plants Just Had Their Worst Year Since the 1970s
Natural gas, nuclear, wind, and solar sources had their best years of electrical output ever.
Coronavirus: Emerging Numbers Provide Reasons for Calm
The viral outbreak is serious, but the latest numbers serve as a reminder for investors and individuals to remain objective about the health and economic risks.
Codexis Expects Its Most Important Source of Revenue to Decline in 2020
The company expects a fourth straight year of stagnant product revenue -- and declining gross margin, to boot. Those are noteworthy red flags for investors.
Will Tandem Diabetes Care Keep Its Premium Valuation in 2020?
The insulin pump manufacturer turned in a solid year of progress in 2019, but full-year 2020 guidance might be at odds with initial Wall Street expectations.
Here's Why Codexis Fell as Much as 20.0% Today
The enzyme engineering company reported disappointing full-year 2019 operating results.
Here's Why Beyond Meat Stock Tumbled as Much as 19.9% Today
The animal-free protein company reported full-year 2019 operating results and provided guidance for the year ahead.
Will Puma Biotechnology Break Out of Its Rut in 2020?
The company's only drug product encountered significant obstacles to increasing its market share in 2019, but investors can see a potential path to growth.
Here's Why NeoGenomics Fell as Much as 20.2% Today
The cancer genetics company reported full-year 2019 operating results, but that's probably not the reason for the decline.
Here's Why Vir Biotechnology Rose as Much as 100.1% Today
The company announced a partnership in its efforts to develop monoclonal antibodies capable of neutralizing the novel coronavirus strain.
Lithium Demand Could Triple by 2025. Does the World Have Enough?
Peak oil has faded from the national lexicon, but some are now worrying about lithium supply. There's legitimate cause for concern, although not for the reason investors might think.